...
nbix-img

Neurocrine Biosciences Inc, Common Stock

NBIX

NSQ

$136.53

-$0.46

(-0.34%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$13.82B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
36.408
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.35
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$110.95 L
$157.98 H
$136.53

About Neurocrine Biosciences Inc, Common Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNBIXSectorS&P500
1-Week Return-0.12%-0.33%-1.49%
1-Month Return7.41%-4.57%-0.37%
3-Month Return17.2%-9.96%3.89%
6-Month Return2.18%-5.67%9.34%
1-Year Return4.07%2.53%25.19%
3-Year Return61.59%-1.43%24.7%
5-Year Return25.19%34.73%85.39%
10-Year Return540.08%102.14%187.19%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue788.10M1.05B1.13B1.49B1.89B[{"date":"2019-12-31","value":41.76,"profit":true},{"date":"2020-12-31","value":55.42,"profit":true},{"date":"2021-12-31","value":60.07,"profit":true},{"date":"2022-12-31","value":78.89,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue7.40M10.10M14.30M23.20M39.70M[{"date":"2019-12-31","value":18.64,"profit":true},{"date":"2020-12-31","value":25.44,"profit":true},{"date":"2021-12-31","value":36.02,"profit":true},{"date":"2022-12-31","value":58.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit780.70M1.04B1.12B1.47B1.85B[{"date":"2019-12-31","value":42.26,"profit":true},{"date":"2020-12-31","value":56.07,"profit":true},{"date":"2021-12-31","value":60.58,"profit":true},{"date":"2022-12-31","value":79.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin99.06%99.03%98.74%98.44%97.90%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.97,"profit":true},{"date":"2021-12-31","value":99.67,"profit":true},{"date":"2022-12-31","value":99.37,"profit":true},{"date":"2023-12-31","value":98.82,"profit":true}]
Operating Expenses554.10M708.30M911.40M1.22B1.60B[{"date":"2019-12-31","value":34.71,"profit":true},{"date":"2020-12-31","value":44.37,"profit":true},{"date":"2021-12-31","value":57.09,"profit":true},{"date":"2022-12-31","value":76.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income219.15M318.90M196.90M249.00M250.90M[{"date":"2019-12-31","value":68.72,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":61.74,"profit":true},{"date":"2022-12-31","value":78.08,"profit":true},{"date":"2023-12-31","value":78.68,"profit":true}]
Total Non-Operating Income/Expense(204.61M)(89.10M)(26.90M)(42.20M)76.60M[{"date":"2019-12-31","value":-267.12,"profit":false},{"date":"2020-12-31","value":-116.32,"profit":false},{"date":"2021-12-31","value":-35.12,"profit":false},{"date":"2022-12-31","value":-55.09,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income46.50M106.70M101.40M213.90M332.10M[{"date":"2019-12-31","value":14,"profit":true},{"date":"2020-12-31","value":32.13,"profit":true},{"date":"2021-12-31","value":30.53,"profit":true},{"date":"2022-12-31","value":64.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes9.50M(300.60M)11.80M59.40M82.40M[{"date":"2019-12-31","value":11.53,"profit":true},{"date":"2020-12-31","value":-364.81,"profit":false},{"date":"2021-12-31","value":14.32,"profit":true},{"date":"2022-12-31","value":72.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes37.00M407.30M89.60M154.50M249.70M[{"date":"2019-12-31","value":9.08,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":61.31,"profit":true}]
Income From Continuous Operations37.01M407.30M89.60M154.50M191.00M[{"date":"2019-12-31","value":9.09,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":46.89,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income37.00M407.30M89.60M154.50M249.70M[{"date":"2019-12-31","value":9.08,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":61.31,"profit":true}]
EPS (Diluted)0.331.301.321.532.42[{"date":"2019-12-31","value":13.64,"profit":true},{"date":"2020-12-31","value":53.72,"profit":true},{"date":"2021-12-31","value":54.55,"profit":true},{"date":"2022-12-31","value":63.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NBIX
Cash Ratio 2.86
Current Ratio 4.37
Quick Ratio 4.26

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NBIX
ROA (LTM) 11.80%
ROE (LTM) 16.35%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NBIX
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NBIX
Trailing PE 36.41
Forward PE 19.05
P/S (TTM) 6.16
P/B 5.10
Price/FCF 92
EV/R 5.75
EV/Ebitda 23.19
PEG 0.32

FAQs

What is Neurocrine Biosciences Inc share price today?

Neurocrine Biosciences Inc (NBIX) share price today is $136.53

Can Indians buy Neurocrine Biosciences Inc shares?

Yes, Indians can buy shares of Neurocrine Biosciences Inc (NBIX) on Vested. To buy Neurocrine Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NBIX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Neurocrine Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Neurocrine Biosciences Inc (NBIX) via the Vested app. You can start investing in Neurocrine Biosciences Inc (NBIX) with a minimum investment of $1.

How to invest in Neurocrine Biosciences Inc shares from India?

You can invest in shares of Neurocrine Biosciences Inc (NBIX) via Vested in three simple steps:

  • Click on Sign Up or Invest in NBIX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Neurocrine Biosciences Inc shares
What is Neurocrine Biosciences Inc 52-week high and low stock price?

The 52-week high price of Neurocrine Biosciences Inc (NBIX) is $157.98. The 52-week low price of Neurocrine Biosciences Inc (NBIX) is $110.95.

What is Neurocrine Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Neurocrine Biosciences Inc (NBIX) is 36.408

What is Neurocrine Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Neurocrine Biosciences Inc (NBIX) is 5.10

What is Neurocrine Biosciences Inc dividend yield?

The dividend yield of Neurocrine Biosciences Inc (NBIX) is 0.00%

What is the Market Cap of Neurocrine Biosciences Inc?

The market capitalization of Neurocrine Biosciences Inc (NBIX) is $13.82B

What is Neurocrine Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Neurocrine Biosciences Inc is NBIX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top